Last reviewed · How we verify

NCT03874806

Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block

Withdrawn Phase 4 Last updated 15 July 2019
What this trial tests

Phase 4 trial testing Ropivacaine 0.25%-NaCl 0.9% Injectable Solution in Pain, Postoperative. Withdrawn.

Timeline
1 July 2019
Primary endpoint
1 July 2020
31 December 2020

Quick facts

Lead sponsorVirginia Commonwealth University
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposesupportive care
Start date1 July 2019
Primary completion1 July 2020
Estimated completion31 December 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Virginia Commonwealth University

Who can join

18 and older, any sex, with Pain, Postoperative or Pain, Chest. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goals of this study are as follows: 1. to confirm the safe dosing of ropivacaine for the erector spinae plane block 2. develop a pharmacokinetic profile of the erector spinae plane block, which will help demonstrate how quickly and how closely toxic levels are reached when a routine dose of ropivacaine is given for this nerve block 3. assess numbness created by the erector spinae block when routine doses are administered

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ropivacaine 0.25%-NaCl 0.9% Injectable Solution

Trials testing the same drug.

Other recruiting trials for Pain, Postoperative

Currently open trials in the same condition.

Other Virginia Commonwealth University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03874806.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing